Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
06/21ASTELLAS PHARMA : Patent Application Titled "Cell Culturing Method Using Nucleic..
AQ
06/21ASTELLAS PHARMA : Researchers from Astellas Pharma Detail Findings in Psoriasis ..
AQ
06/15ASTELLAS PHARMA INC : Proxy Statments
CO
06/14SEATTLE GENETICS : and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Pa..
AQ
06/14ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/14ASTELLAS PHARMA : Studies from Astellas Pharma Provide New Data on Diabetic Neph..
AQ
06/13PFIZER : Astellas Announces Launch of XTANDI Tablets in Japan for the Treatment ..
AQ
06/11VICAL INCORPORATED : discontinuing HSV-2 program after Phase II miss
AQ
06/11ASTELLAS PHARMA : Announces Launch of XTANDI® Tablets in Japan for the Treatment..
PU
06/07ASTELLAS PHARMA : New Findings in Medicinal Chemistry Described from Astellas Ph..
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/18Aptinyx Proposes Final Terms For $80 Million IPO 
06/12Vical Becomes An Attractive Speculative Play After Latest Clinical Trial Blun.. 
05/31YOUR DAILY PHARMA SCOOP : 4 NDAs... CPRX, EXEL, ALPMY, ACOR 
05/29FDA accepts Astellas' marketing application for gilteritinib for AML 
Financials ( JPY)
Sales 2019 1 287 B
EBIT 2019 264 B
Net income 2019 206 B
Finance 2019 395 B
Yield 2019 2,17%
P/E ratio 2019 16,43
P/E ratio 2020 18,20
EV / Sales 2019 2,40x
EV / Sales 2020 2,38x
Capitalization 3 481 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 698  JPY
Spread / Average Target -3,4%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda General Manager-Pharmaceutical Technology
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC21.24%31 635
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.80%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785
MERCK AND COMPANY9.24%165 373